DILTIAZEM TEVA L.P. 300 mg, extended-release capsule 28 capsules
Active ingredients: Diltiazem hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DILTIAZEM TEVA L.P. 300 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 28 gélule(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 25 Apr 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68238848CIP73616003CIP133400936160033Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE DILTIAZEMgélule | 300 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.